Home LiteratureArticle Details
PMID: 18047744 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Review

Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting.

BMC biochemistry ·Vol. 8 Suppl 1 ·2007-11-22 ·Pages S7

Nury D, Doucet C, Coux O

Abstract

Muscle wasting, characterized by the loss of protein mass in myofibers, is in most cases largely due to the activation of intracellular protein degradation by the ubiquitin proteasome system (UPS). During the last decade, mechanisms contributing to this activation have been unraveled and key mediators of this process identified. Even though much remains to be understood, the available information already suggests screens for new compounds inhibiting these mechanisms and highlights the potential for pharmaceutical drugs able to treat muscle wasting when it becomes deleterious. This review presents an overview of the main pathways contributing to UPS activation in muscle and describes the present state of efforts made to develop new strategies aimed at blocking or slowing muscle wasting. Publication history: Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com).

MeSH Terms
Animals Drug Delivery Systems/methods,trends Enzyme Inhibitors/pharmacology,therapeutic use Humans Muscular Atrophy/drug therapy,enzymology Proteasome Endopeptidase Complex/metabolism Proteasome Inhibitors Ubiquitin-Protein Ligase Complexes/antagonists & inhibitors,metabolism
Chemicals
Enzyme Inhibitors Proteasome Inhibitors Ubiquitin-Protein Ligase Complexes Proteasome Endopeptidase Complex
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Nury David
CRBM-CNRS UMR5237, IFR22, 1919 route de Mende, 34000 Montpellier, France. david.nury@crbm.cnrs.fr
Doucet Christine
Coux Olivier
References (116)
116 references, click to expand
  1. Skeletal muscle hypertrophy and atrophy signaling pathways.
    Int J Biochem Cell Biol. 2005 Oct;37(10):1974-84 PMID: 16087388
  2. Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibers but not muscle growth.
    Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13108-13 PMID: 11606756
  3. Cachexia: pathophysiology and clinical relevance.
    Am J Clin Nutr. 2006 Apr;83(4):735-43 PMID: 16600922
  4. Intracellular signaling during skeletal muscle atrophy.
    Muscle Nerve. 2006 Feb;33(2):155-65 PMID: 16228971
  5. The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting.
    J Support Oncol. 2005 May-Jun;3(3):209-17 PMID: 15915823
  6. Mechanism of induction of muscle protein degradation by angiotensin II.
    Cell Signal. 2006 Jul;18(7):1087-96 PMID: 16257180
  7. Proteolysis: from the lysosome to ubiquitin and the proteasome.
    Nat Rev Mol Cell Biol. 2005 Jan;6(1):79-87 PMID: 15688069
  8. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy.
    Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14440-5 PMID: 11717410
  9. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex.
    Nature. 2000 Nov 16;408(6810):381-6 PMID: 11099048
  10. Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex.
    J Clin Invest. 2004 Oct;114(8):1058-71 PMID: 15489953
  11. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation.
    Br J Cancer. 2004 Nov 1;91(9):1742-50 PMID: 15477867
  12. Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass.
    FASEB J. 2004 Jun;18(9):1025-7 PMID: 15084522
  13. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid.
    Cancer Res. 2001 May 1;61(9):3604-9 PMID: 11325828
  14. Regulation of proteolysis during reloading of the unweighted soleus muscle.
    Int J Biochem Cell Biol. 2003 May;35(5):665-75 PMID: 12672458
  15. Gene therapy with anabolic growth factors to prevent muscle atrophy.
    Curr Opin Clin Nutr Metab Care. 2006 May;9(3):207-13 PMID: 16607118
  16. Differential gene expression profiling of short and long term denervated muscle.
    FASEB J. 2006 Jan;20(1):115-7 PMID: 16291642
  17. Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles.
    Biochem J. 2004 Feb 15;378(Pt 1):239-46 PMID: 14636157
  18. A multicomponent system that degrades proteins conjugated to ubiquitin. Resolution of factors and evidence for ATP-dependent complex formation.
    J Biol Chem. 1988 Sep 5;263(25):12412-9 PMID: 2842333
  19. Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat.
    Am J Physiol Gastrointest Liver Physiol. 2004 Dec;287(6):G1124-30 PMID: 15256363
  20. Proteasome inhibition in multiple myeloma: therapeutic implication.
    Annu Rev Pharmacol Toxicol. 2005;45:465-76 PMID: 15822185
  21. Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.
    Cancer Res. 2004 Sep 15;64(18):6725-31 PMID: 15374990
  22. IKKbeta/NF-kappaB activation causes severe muscle wasting in mice.
    Cell. 2004 Oct 15;119(2):285-98 PMID: 15479644
  23. Ubiquitin signalling in the NF-kappaB pathway.
    Nat Cell Biol. 2005 Aug;7(8):758-65 PMID: 16056267
  24. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.
    J Exp Med. 1993 Jun 1;177(6):1675-80 PMID: 8496685
  25. Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels.
    J Toxicol Clin Toxicol. 2001;39(4):339-44 PMID: 11527226
  26. Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, Ca2+ -activated, and ubiquitin-proteasome proteolytic pathways.
    J Clin Invest. 1996 Apr 1;97(7):1610-7 PMID: 8601625
  27. Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3alpha-II during cancer cachexia.
    Cancer Res. 2004 Nov 15;64(22):8193-8 PMID: 15548684
  28. Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I.
    Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18135-40 PMID: 15601779
  29. USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states.
    Am J Physiol Endocrinol Metab. 2005 Apr;288(4):E693-700 PMID: 15562254
  30. The kinase domain of titin controls muscle gene expression and protein turnover.
    Science. 2005 Jun 10;308(5728):1599-603 PMID: 15802564
  31. On our way to targeted therapy for cachexia in cancer?
    Curr Opin Oncol. 2006 Jul;18(4):335-40 PMID: 16721127
  32. Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1.
    J Cell Biol. 2002 Apr 1;157(1):125-36 PMID: 11927605
  33. Ubiquitin-proteasome-dependent proteolysis in skeletal muscle.
    Reprod Nutr Dev. 1998 Mar-Apr;38(2):153-65 PMID: 9638789
  34. A family of mammalian E3 ubiquitin ligases that contain the UBR box motif and recognize N-degrons.
    Mol Cell Biol. 2005 Aug;25(16):7120-36 PMID: 16055722
  35. Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression.
    FASEB J. 2004 Jan;18(1):39-51 PMID: 14718385
  36. IGF-1 is downregulated in experimental cancer cachexia.
    Am J Physiol Regul Integr Comp Physiol. 2006 Sep;291(3):R674-83 PMID: 16614058
  37. Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats.
    J Clin Invest. 1999 Nov;104(10):1411-20 PMID: 10562303
  38. Regulation of ATP-ubiquitin-dependent proteolysis in muscle wasting.
    Reprod Nutr Dev. 1994;34(6):583-97 PMID: 7840873
  39. Felix Hoppe-Seyler Lecture 2000. The ubiquitin system and the N-end rule pathway.
    Biol Chem. 2000 Sep-Oct;381(9-10):779-89 PMID: 11076011
  40. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF).
    Br J Cancer. 2001 Jul 20;85(2):297-302 PMID: 11461093
  41. Post burn muscle wasting and the effects of treatments.
    Int J Biochem Cell Biol. 2005 Oct;37(10):1948-61 PMID: 16109499
  42. Ubiquitin-binding domains.
    Nat Rev Mol Cell Biol. 2005 Aug;6(8):610-21 PMID: 16064137
  43. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway.
    N Engl J Med. 1996 Dec 19;335(25):1897-905 PMID: 8948566
  44. Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia.
    Br J Cancer. 2005 Oct 3;93(7):774-80 PMID: 16160695
  45. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy.
    Mol Cell Biol. 2004 Nov;24(21):9295-304 PMID: 15485899
  46. The ubiquitin-proteasome proteolytic pathway in heart vs skeletal muscle: effects of acute diabetes.
    Biochem Biophys Res Commun. 2000 Oct 5;276(3):1255-60 PMID: 11027619
  47. MURF-1 and MURF-2 target a specific subset of myofibrillar proteins redundantly: towards understanding MURF-dependent muscle ubiquitination.
    J Mol Biol. 2005 Jul 22;350(4):713-22 PMID: 15967462
  48. Lysosomal proteolysis in skeletal muscle.
    Int J Biochem Cell Biol. 2005 Oct;37(10):2098-114 PMID: 16125113
  49. Identification of pathways controlling muscle protein metabolism in uremia and other catabolic conditions.
    Curr Opin Nephrol Hypertens. 2005 Jul;14(4):378-82 PMID: 15931008
  50. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control.
    J Biol Chem. 2004 Sep 24;279(39):41114-23 PMID: 15272020
  51. Developmental changes of the primary structure and histidine methylation in rabbit skeletal muscle myosin.
    Nat New Biol. 1972 Dec 27;240(104):260-4 PMID: 4512226
  52. Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization.
    FASEB J. 2004 Feb;18(2):227-37 PMID: 14769817
  53. Calpains in muscle wasting.
    Int J Biochem Cell Biol. 2005 Oct;37(10):2115-33 PMID: 16125114
  54. Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways.
    Nat Cell Biol. 2001 Nov;3(11):1009-13 PMID: 11715022
  55. Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects.
    Exp Cell Res. 2006 Aug 1;312(13):2401-14 PMID: 16793037
  56. Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism.
    J Cell Physiol. 2006 Nov;209(2):501-14 PMID: 16883577
  57. Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future.
    Nutrition. 2005 Sep;21(9):977-85 PMID: 16043325
  58. Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle.
    Int J Biochem Cell Biol. 2003 May;35(5):698-705 PMID: 12672461
  59. Ubiquitin-protein ligases in muscle wasting: multiple parallel pathways?
    Curr Opin Clin Nutr Metab Care. 2003 May;6(3):271-5 PMID: 12690258
  60. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.
    Mol Cell. 2004 May 7;14(3):395-403 PMID: 15125842
  61. Degradation of a cohesin subunit by the N-end rule pathway is essential for chromosome stability.
    Nature. 2001 Apr 19;410(6831):955-9 PMID: 11309624
  62. Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study.
    Cancer Immunol Immunother. 1993;36(1):57-60 PMID: 7678547
  63. Ca(2+)-dependent proteolysis in muscle wasting.
    Int J Biochem Cell Biol. 2005 Oct;37(10):2134-46 PMID: 15893952
  64. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
    Exp Neurol. 2006 Mar;198(1):234-41 PMID: 16410003
  65. Drug discovery in the ubiquitin-proteasome system.
    Nat Rev Drug Discov. 2006 Jul;5(7):596-613 PMID: 16816840
  66. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.
    J Clin Oncol. 1995 Nov;13(11):2856-9 PMID: 7595749
  67. Signal-transduction networks and the regulation of muscle protein degradation.
    Int J Biochem Cell Biol. 2005 Oct;37(10):1997-2011 PMID: 16125109
  68. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles.
    J Clin Invest. 1997 Jul 1;100(1):197-203 PMID: 9202072
  69. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states.
    J Am Soc Nephrol. 2006 Jul;17(7):1807-19 PMID: 16738015
  70. The ubiquitin-proteasome system and skeletal muscle wasting.
    Essays Biochem. 2005;41:173-86 PMID: 16250905
  71. Activation of ubiquitin-proteasome pathway is involved in skeletal muscle wasting in a rat model with biliary cirrhosis: potential role of TNF-alpha.
    Am J Physiol Endocrinol Metab. 2005 Mar;288(3):E493-501 PMID: 15522995
  72. Mechanically induced titin kinase activation studied by force-probe molecular dynamics simulations.
    Biophys J. 2005 Feb;88(2):790-804 PMID: 15531631
  73. Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats.
    J Physiol. 2004 Feb 15;555(Pt 1):175-88 PMID: 14617677
  74. The 26S proteasome: a molecular machine designed for controlled proteolysis.
    Annu Rev Biochem. 1999;68:1015-68 PMID: 10872471
  75. Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts.
    J Biol Chem. 1996 Oct 25;271(43):26690-7 PMID: 8900146
  76. Clinical anticachexia treatments.
    Nutr Clin Pract. 2006 Apr;21(2):168-74 PMID: 16556927
  77. Ubiquitin-protein ligases--novel therapeutic targets?
    Curr Protein Pept Sci. 2004 Jun;5(3):163-76 PMID: 15180521
  78. Inactivation of the HR6B ubiquitin-conjugating DNA repair enzyme in mice causes male sterility associated with chromatin modification.
    Cell. 1996 Sep 6;86(5):799-810 PMID: 8797826
  79. Insights into muscle atrophy and recovery pathway based on genetic models.
    Curr Opin Clin Nutr Metab Care. 2006 Jul;9(4):395-402 PMID: 16778568
  80. Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy.
    FASEB J. 2002 Apr;16(6):529-38 PMID: 11919155
  81. Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway.
    J Appl Physiol (1985). 2005 Jul;99(1):71-80 PMID: 15774696
  82. Sepsis-induced muscle proteolysis is prevented by a proteasome inhibitor in vivo.
    Biochem Biophys Res Commun. 2000 Apr 2;270(1):215-21 PMID: 10733930
  83. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.
    Cell. 2004 Apr 30;117(3):399-412 PMID: 15109499
  84. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors.
    Trends Cell Biol. 2005 Jan;15(1):27-33 PMID: 15653075
  85. NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle.
    Br J Cancer. 2005 Feb 28;92(4):711-21 PMID: 15714207
  86. The AP-1/CJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia.
    FEBS Lett. 2006 Jan 23;580(2):691-6 PMID: 16412434
  87. Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting.
    Biochem J. 2001 Nov 15;360(Pt 1):143-50 PMID: 11696001
  88. Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin-proteasome-dependent proteolysis in cancer and septic rats.
    Biochem J. 2002 Jan 15;361(Pt 2):185-92 PMID: 11772390
  89. Effects of insulin, glucose, and amino acids on protein turnover in rat diaphragm.
    J Biol Chem. 1975 Jan 10;250(1):290-8 PMID: 1141208
  90. Identification of ubiquitin ligases required for skeletal muscle atrophy.
    Science. 2001 Nov 23;294(5547):1704-8 PMID: 11679633
  91. Increased transcription of ubiquitin-proteasome system components: molecular responses associated with muscle atrophy.
    Int J Biochem Cell Biol. 2003 May;35(5):617-28 PMID: 12672454
  92. TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle.
    FASEB J. 2005 Mar;19(3):362-70 PMID: 15746179
  93. Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase.
    J Biol Chem. 2005 Jan 28;280(4):2847-56 PMID: 15531760
  94. Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview.
    Fed Proc. 1978 Jul;37(9):2291-300 PMID: 350635
  95. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions.
    J Clin Invest. 2004 Jan;113(1):115-23 PMID: 14702115
  96. Ubiquitin-proteasome-dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats.
    J Physiol. 2003 Feb 1;546(Pt 3):765-76 PMID: 12563002
  97. Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes.
    J Biol Chem. 1980 Aug 25;255(16):7525-8 PMID: 6249802
  98. A targeted deletion of the C-terminal end of titin, including the titin kinase domain, impairs myofibrillogenesis.
    J Cell Sci. 2003 Dec 1;116(Pt 23):4811-9 PMID: 14600266
  99. Conditional expression of mutant M-line titins results in cardiomyopathy with altered sarcomere structure.
    J Biol Chem. 2003 Feb 21;278(8):6059-65 PMID: 12464612
  100. A soluble ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes.
    Proc Natl Acad Sci U S A. 1977 Jan;74(1):54-8 PMID: 264694
  101. Proteomic analysis of altered protein expression in skeletal muscle of rats in a hypermetabolic state induced by burn sepsis.
    Biochem J. 2006 Jul 1;397(1):149-58 PMID: 16483253
  102. Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats.
    Mol Biol Rep. 1999 Apr;26(1-2):95-101 PMID: 10363654
  103. Molecular determinants of skeletal muscle mass: getting the "AKT" together.
    Int J Biochem Cell Biol. 2005 Oct;37(10):1985-96 PMID: 16125108
  104. Control of ubiquitination in skeletal muscle wasting.
    Int J Biochem Cell Biol. 2005 Oct;37(10):2075-87 PMID: 16125111
  105. Ubiquitin-conjugating enzyme E214k/HR6B is dispensable for increased protein catabolism in muscle of fasted mice.
    Am J Physiol Endocrinol Metab. 2002 Sep;283(3):E482-9 PMID: 12169441
  106. Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model.
    Gene Ther. 1999 Jan;6(1):91-7 PMID: 10341880
  107. Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway.
    Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12602-7 PMID: 9770532
  108. Mechanism of muscle protein degradation induced by a cancer cachectic factor.
    Br J Cancer. 1998 Oct;78(7):850-6 PMID: 9764574
  109. Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling.
    Endocrinology. 2006 Sep;147(9):4160-8 PMID: 16777975
  110. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial.
    Gut. 2005 Apr;54(4):540-5 PMID: 15753541
  111. Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase.
    J Am Soc Nephrol. 2004 Jun;15(6):1537-45 PMID: 15153564
  112. Construction and analysis of mouse strains lacking the ubiquitin ligase UBR1 (E3alpha) of the N-end rule pathway.
    Mol Cell Biol. 2001 Dec;21(23):8007-21 PMID: 11689692
  113. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1.
    Am J Physiol Endocrinol Metab. 2004 Oct;287(4):E591-601 PMID: 15100091
  114. Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy.
    J Am Soc Nephrol. 2006 May;17(5):1388-94 PMID: 16611720
  115. The ubiquitin system.
    Annu Rev Biochem. 1998;67:425-79 PMID: 9759494
  116. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states.
    J Nutr. 1999 Jan;129(1S Suppl):227S-237S PMID: 9915905
Article Info
Journal
BMC biochemistry
Abbr.
BMC Biochem
ISSN
1471-2091
DOI
10.1186/1471-2091-8-S1-S7
Email
david.nury@crbm.cnrs.fr
Published
2007-11-22
Epub
2007-00-22
Pages
S7
Language
English
Region
England
NLM ID
101084098
PMCID
PMC2106371
Subset
IM
External Links
PubMed source DOI: 10.1186/1471-2091-8-S1-S7 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2